You have 9 free searches left this month | for more free features.

CD40L

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Tumor-infiltrating Lymphocytes (TIL)
  • +5 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 28, 2022

Type 1 Diabetes Trial in Vancouver (Frexalimab, Placebo, Insulin)

Recruiting
  • Type 1 Diabetes Mellitus
  • Vancouver, British Columbia, Canada
    Investigational Site Number : 1240001
Oct 31, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in United States (SL-172154)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Duarte, California
  • +8 more
Feb 23, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck Trial in United States (Drug: SL-172154)

Terminated
  • Cutaneous Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Drug: SL-172154
  • Los Angeles, California
  • +5 more
May 18, 2022

Acute Myeloid Leukemia, MDS Trial in United States (SL-172154)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +12 more
Jan 23, 2023

Liver Transplant Rejection Trial in Worldwide (CFZ533, Tacrolimus - MMF - corticosteroids)

Active, not recruiting
  • Liver Transplant Rejection
  • CFZ533
  • Tacrolimus - MMF - corticosteroids
  • Los Angeles, California
  • +28 more
Jan 17, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Belgium, France, Spain (CD40 agonist mitazalimab in combination with chemo)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • CD40 agonist mitazalimab in combination with chemotherapy
  • Brussels, Belgium
  • +15 more
Aug 12, 2022

Breast Carcinoma Trial (rVV-740CTA)

Withdrawn
  • Breast Carcinoma
  • rVV-740CTA
  • (no location specified)
Feb 5, 2020

Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer Trial in Buffalo (other, procedure,

Terminated
  • Recurrent Renal Cell Carcinoma
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 2, 2020

Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,

Recruiting
  • Advanced or Metastatic Solid Tumors
  • CD40 ligand expressing MSLN-CAR T cells
  • +2 more
  • Beijing, Beijing, China
    Kaichao Feng
Jan 19, 2023

Multiple Sclerosis Trial in Worldwide (SAR441344 IV, IV, SAR441344 SC)

Active, not recruiting
  • Multiple Sclerosis
  • SAR441344 IV
  • +4 more
  • Phoenix, Arizona
  • +47 more
Oct 10, 2022

Hematopoietic Organs; Disorder Trial in Hong Kong (CD62L depleted donor lymphocyte infusion)

Recruiting
  • Hematopoietic Organs; Disorder
  • CD62L depleted donor lymphocyte infusion
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Sep 6, 2023

Lung Cancer, Adenocarcinoma of the Lung Trial (Nivolumab, GM.CD40L Vaccine)

Withdrawn
  • Lung Cancer
  • Adenocarcinoma of the Lung
  • (no location specified)
Sep 6, 2019

Lung Cancer, Adenocarcinoma Trial in Tampa (Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase

Completed
  • Lung Cancer
  • Adenocarcinoma
  • Phase I - GM.CD40L.CCL21 Vaccinations
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Aug 5, 2019

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,

Not yet recruiting
  • Biliary Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
May 13, 2023

The Effect of Human Prostate Tissue on Platelet Activation

Completed
  • Prostate Hyperplasia
  • +2 more
    • (no location specified)
    Sep 19, 2021

    Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

    Recruiting
    • Non Small Cell Lung Cancer
    • Lung Cancer
    • FLT3 Ligand (CDX-301)
    • +2 more
    • Bronx, New York
      Albert Einstein College of Medicine
    Jul 18, 2022

    Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

    Recruiting
    • Metastatic Triple Negative Breast Cancer
    • PLD Chemotherapy
    • +2 more
    • Dallas, Texas
      UT Southwestern Medical Center
    Jun 23, 2022

    Immune Thrombocytopenic Purpura Trial in Sohag (Genotyping of rs1883832C/T related single-nucleotide polymorphism)

    Not yet recruiting
    • Immune Thrombocytopenic Purpura
    • Genotyping of rs1883832C/T related single-nucleotide polymorphism
    • Sohag, Egypt
      Sohag University hospitals
    Oct 16, 2022

    Healthy Adults Trial in Créteil (Solo 0.3 group, Solo 1 group, Solo 3 group)

    Recruiting
    • Healthy Adults
    • Solo 0.3 group
    • +5 more
    • Créteil, France
    • +2 more
    Sep 9, 2022

    Solid Tumor Trial (BS006 Injection)

    Not yet recruiting
    • Solid Tumor
    • BS006 Injection
    • (no location specified)
    Jul 3, 2023

    Metastatic Pancreatic Adenocarcinoma Trial (odetiglucan, CDX-1140)

    Not yet recruiting
    • Metastatic Pancreatic Adenocarcinoma
    • odetiglucan
    • CDX-1140
    • (no location specified)
    Jul 29, 2022

    Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

    Not yet recruiting
    • Ovarian Clear Cell Adenocarcinoma
    • +14 more
    • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
    • +4 more
    • Buffalo, New York
    • +1 more
    Dec 16, 2022